Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care A randomized, controlled trial by Wright, Susan P. et al.
Heart Failure
Plasma Amino-Terminal Pro-Brain Natriuretic Peptide
and Accuracy of Heart-Failure Diagnosis in Primary Care
A Randomized, Controlled Trial
Susan P. Wright, MBCHB,* Robert N. Doughty, MD, MRCP, FRACP,*
Ann Pearl, MA (HONS), MBCHB,† Greg D. Gamble, MSC,*
Gillian A. Whalley, MHSCI, DMU,* Helen J. Walsh, BSC,* Gary Gordon, MBCHB, FCP(SA), FRACP,*
Warwick Bagg, MD, FRACP,* Helen Oxenham, MBBS, MRCP,* Tim Yandle, PHD,‡
Mark Richards, MD, PHD, DSC, FACC, FRACP, FRSNZ,‡ Norman Sharpe, MD, FRACP, FACC*
Auckland and Christchurch, New Zealand
OBJECTIVES The purpose of this study was to determine the effect of amino-terminal pro-brain natriuretic
peptide (N-BNP) on the diagnostic accuracy of heart failure (HF) in primary care.
BACKGROUND The accurate diagnosis of patients with suspected HF presenting in primary care is difficult.
Amino-terminal pro-brain natriuretic peptide is present in high levels in cardiac dysfunction
and may improve the diagnostic accuracy of HF in primary care.
METHODS The Natriuretic Peptides in the Community Study was a prospective, randomized controlled
trial of the effect of N-BNP on the accuracy of HF diagnosis. Patients presenting to their
general practitioner (GP) with symptoms of dyspnea and/or peripheral edema were included.
The GPs formulated an initial diagnosis based on clinical assessment. All patients underwent
a full cardiologic assessment that included echocardiography and N-BNP. Each patient was
randomized to the BNP group (GP received the N-BNP result) or the control group (GP did
not receive the N-BNP result). Patients were then reviewed by their GP, and their diagnosis
was reviewed. The primary end point was the accuracy of the GPs’ diagnoses compared with
the panel standard.
RESULTS A total of 305 patients were included; mean age was 72 years, 65% were female.
Seventy-seven patients met the panel criteria for HF. The diagnostic accuracy improved 21%
in the BNP group and 8% in the control group (p  0.002). The main impact of N-BNP
measurement on diagnostic accuracy was the GPs’ correctly ruling out HF. The number
needed to diagnose by N-BNP measurement was seven patients.
CONCLUSION This study demonstrates that N-BNP measurement significantly improves the diagnostic
accuracy of HF by GPs over and above customary clinical review. (J Am Coll Cardiol 2003;
42:1793–800) © 2003 by the American College of Cardiology Foundation
The accurate diagnosis of heart failure (HF) presenting in
primary care is difficult. Clinical assessment of symptoms
and signs has limited sensitivity and specificity (1). The
clinical syndrome of HF is particularly difficult to diagnose
in the elderly and in the presence of accompanying respira-
tory disease (1). For patients diagnosed with HF in primary
care, only a minority have that diagnosis confirmed after
cardiologic assessment (2). Hence, there is a need for a
diagnostic test that can improve the accuracy of HF diag-
nosis in primary care.
Natriuretic peptides are released in response to increased
intra-cardiac volume or pressure and can be assayed on
venous blood samples. Brain natriuretic peptide (BNP),
released mainly by the ventricle, is elevated in HF and offers
promise as a diagnostic test in primary care. The amino-
terminal pro-BNP (N-BNP) fragment, which is secreted in
a 1:1 ratio with the bioactive 32-amino acid carboxy-
terminal fragment (3) is present in higher levels in cardiac
dysfunction (4), so it may be a superior diagnostic discrim-
inator in patients with suspected HF.
Measurement of BNP is useful in the assessment of
patients with acute dyspnea referred to the hospital (5–8)
and patients with suspected HF referred to a rapid access
hospital clinic (9). In newly symptomatic patients with
suspected HF referred to a rapid access clinic, BNP had
high negative predictive value, which is particularly impor-
tant when community diagnosis depends on relatively non-
specific clinical criteria (9).
However, not all community-based BNP studies are
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consistent with studies in the hospital or clinic setting.
Observational and cross-sectional studies performed in pri-
mary care cohorts show poorer correlation of BNP with
indices of HF such as the degree of left ventricular (LV)
dysfunction (10) and prescription of frusemide (11). Brain
natriuretic peptide can be elevated by many common con-
ditions, including renal impairment (12), myocardial infarc-
tion (13), chronic lung disease (14), hypertension and LV
hypertrophy (15), atrial fibrillation (AF) (16), valvular heart
disease (17), thyroid disorders (18), and age itself (19,20).
Brain natriuretic peptide may also be decreased by common
cardiovascular medications, including loop diuretics (21,22)
and angiotensin-converting enzyme (ACE) inhibitors
(23,24), and thus may be normal in patients with compen-
sated chronic HF.
Novel diagnostic technologies are often implemented
before evidence of their accuracy and clinical utility has been
established in the population of interest. Ideally, new tests
should be assessed in an unselected consecutive series of
patients presenting with symptoms of the disease in primary
care (25). The Natriuretic Peptides in the Community
Study is the first prospective, randomized controlled trial to
determine the effect of N-BNP on the accuracy of HF
diagnosis in the community. Randomization of plasma
N-BNP measurements allowed this test to be assessed
against customary diagnostic practice in the “real world”
setting of health care in the community.
METHODS
Patients. Patients 40 years of age or more presenting to
their general practitioner (GP) with symptoms of dyspnea
and/or edema of recent onset were eligible for this study.
Patients could have comorbid medical conditions and could
have been receiving any treatment. Patients were excluded if
they required urgent admission to the hospital or were
unable to provide informed consent. Further exclusions
were hospital admission with a diagnosis of HF, echocar-
diography for assessment of LV function, or outpatient
cardiologic assessment for the evaluation of dyspnea or
edema during the previous 12 months. The Auckland
Ethics Committee approved the study. All patients pro-
vided written informed consent.
Study design. Eligible patients presenting to participating
GPs with dyspnea and/or edema were referred to the study
by their GPs. At this visit (Initial GP Visit, Fig. 1), the GPs
recorded whether or not HF was suspected on the basis of
patient history and clinical examination (the initial GP
diagnosis). Commencement of any treatment was at GP
discretion.
Patients were contacted within 24 h of the initial GP visit
and booked to attend a study visit (Study Visit, Fig. 1). At
this visit, each patient was assessed clinically by a cardiolo-
gist, and electrocardiography, chest radiograph, blood col-
lection for N-BNP measurement, and transthoracic echo-
cardiography (Philips HDI 5000, Bothell, Seattle,
Washington) were performed. Blood was collected using
standard venepuncture technique into tubes containing
ethylenediaminetetraacetic acid. Samples were centrifuged
and frozen at 70°C. The N-BNP was measured by
radioimmunoassay at the CardioEndocrine Research Lab-
oratory, Christchurch, New Zealand (4).
An independent study investigator performed computer
randomization with the patient as the unit of randomiza-
tion. Each patient was randomly allocated to either the
BNP group or the control group. Patients in the BNP group
had their N-BNP result faxed to their GPs with a standard-
ized interpretative comment (Table 1). This included the
laboratory normal range for N-BNP (0 to 50 pmol/l) and
the range in which HF was very likely (150 pmol/l) (5).
Patients in the control group had a laboratory results sheet
faxed to their GPs informing them that their patients’
N-BNP results were not available.
At the time of this study, BNP measurement was not
routinely available to GPs in Auckland. Before the study, all
GPs received a standardized 30-min education session on
the interpretation of N-BNP and were asked to apply the
interpretative comment shown in Table 1.
Patients were then reviewed by their GPs (GP review
visit, Fig. 1), either with their N-BNP result (BNP group)
or according to customary clinical assessment (control
group). A final diagnosis was made by the GP at this visit.
Panel standard diagnosis of HF. The definite reference
test for the purposes of this study was a clinical diagnosis of
HF made by a panel of four experts (three cardiologists and
one GP) using the rigorous application of pre-defined
criteria. Panel members were independent of all study
procedures and were blinded to each patient’s group alloca-
tion and N-BNP result. The panel reviewed all clinical data
for each patient, including electrocardiogram, chest radio-
graph, and echocardiograph (but excluding natriuretic pep-
tide measurements), and decided whether each individual
met the case definition of HF. The panel decision was based
on the European Society of Cardiology Working Group on
HF diagnostic criteria (26). To meet the case definition of
HF, patients had to have appropriate symptoms and clinical
signs of pulmonary or peripheral congestion in the presence
of objective evidence of cardiac dysfunction. If doubt re-
mained, a beneficial response to treatment was considered.
The panel standard used in this study was based on previous
studies of the diagnosis of HF (9,27).
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
BNP  brain natriuretic peptide
GP  general practitioner
HF  heart failure
IQR  interquartile range
LV  left ventricular
N-BNP  amino-terminal pro-brain natriuretic peptide
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Study end point. The primary study end point was GP
accuracy in the final diagnosis of the BNP and control
groups. This was measured as percent correct final diagnoses
in each group compared with the panel standard.
Statistical analysis. Preliminary estimates of the diagnostic
accuracy of HF in general practice suggested that two
groups of 100 patients each would be required to show a
20% absolute increase in diagnostic accuracy (assuming 5%
significance and 80% power). However, it was understood
that this estimate would need to be refined during the study,
depending on the patients who were referred. Thus, a
pre-planned re-estimate of the sample size was completed
after the first 100 participants were recruited. To maintain
an overall 5% significance level, the Bonferroni correction
was applied to the critical value. For the main result to
maintain a 5% statistical significance level after this interim
analysis, a p value of 0.025 (for a two-tailed test) was
required. This interim analysis resulted in an increase of the
required sample size to 300 (150 patients in each group).
The proportion of correct diagnoses of HF in the BNP
and control groups was compared using the Fisher exact
test. The Fisher exact test was also used to examine the
change in diagnostic accuracy before (Initial GP Visit) and
after (GP Review Visit) N-BNP results were made avail-
able. Comparisons of continuous variables were performed
using the Student t test (normally distributed variables) and
Wilcoxon’s test (non-normally distributed variables). In
multivariate analysis, the change in correct diagnosis be-
tween first and second GP visits was modeled using logistic
regression to test the effect of N-BNP results on the
accuracy of diagnosis after adjusting for the potentially
confounding effect of treatment with loop diuretics, ACE
Figure 1. Trial profile. GP  general practitioner; N-BNP  amino-terminal pro-brain natriuretic peptide.
Table 1. Standardized Interpretative Advice Accompanying
N-BNP Results
Comment
1. Normal range in healthy subjects, N-BNP  50 pmol/l.
2. N-BNP  150 pmol/l strongly suggests HF in a newly symptomatic
patient, but all clinical information should be taken into account.
3. In between these levels, HF is still possible, but all available clinical
information must be taken into account. N-BNP may be elevated by
renal impairment, atrial fibrillation, LVH, COPD, after myocardial
infarction, in the elderly and by treatment with beta-blockers or
digoxin. N-BNP may be decreased by hypothyroidism, treatment
with diuretics, vasodilators, and ACE inhibitors.
ACE  angiotensin-converting enzyme; COPD  chronic obstructive pulmonary
disease; HF  heart failure; LVH  left ventricular hypertrophy; N-BNP  amino-
terminal pro-brain natriuretic peptide.
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inhibitor medications, and time between GP visits. Number
needed to diagnose analysis was performed using change in
the absolute numbers of correct diagnoses. All tests were
two-tailed, and a 5% significance level was maintained
throughout.
RESULTS
Baseline characteristics. Ninety-two GPs referred a total
of 319 patients with symptoms of dyspnea and/or edema to
the study (Fig. 1), of whom 307 consented to the study. One
patient later withdrew consent, and one patient was unable
to attend a study visit. The remaining 305 patients are
included in this report. The BNP and control groups were
comparable at baseline, except for a minor difference in
mean age (p  0.04) (Table 2). The mean age of the overall
group was 72 years (range 40 to 95 years), and 65% were
female. A total of 49% of patients presented with dyspnea
only, 12% with edema only, and 39% with both symptoms.
Although the majority appeared to have New York Heart
Association class II symptoms, functional ability assessed by
a 6-min walk distance was markedly impaired (mean 262
meters), reflecting an elderly cohort of patients with multi-
system disease. Comorbid diagnoses were common (Table
2), and 35 patients (11%) were in AF.
The median delay between a patient’s initial GP visit and
attendance at the study visit was seven days (interquartile
range [IQR] 5 to 11). The median delay between patient
attendance at the study visit and attendance at the GP
review visit was 24 days (IQR 18 to 29).
GP diagnosis of HF and the panel standard. The initial
diagnostic impression of referring GPs based on patient
history and examination was that 215 (70%) patients had
HF. However, only 77 patients (25%) were allocated a
diagnosis of HF by the panel. The consistency of the panel
standard diagnosis of HF was assessed by the representation
to the panel of a random sample of 10% of patients; kappa
coefficient  0.81. The receiver operating characteristic
curve for N-BNP is shown in Figure 2, with area under the
curve  0.85. The sensitivity and specificity were maxi-
mized at a cutoff of N-BNP 100 pmol/l.
Table 2. Baseline Characteristics
BNP Group
(n  153)
Control Group
(n  152) p Value
Age (yrs)* 69 (11) 72 (11) 0.04
Gender, female 101 (66) 97 (64) 0.63
Ethnicity
Caucasian 120 (39) 117 (38) —
Maori/Pacific Island 22 (7) 21 (7) —
Asian 10 (3) 15 (5) 0.79
Symptoms
Dyspnea only 64 (42) 54 (35) —
Edema only 15 (10) 23 (15) —
Both symptoms 73 (48) 76 (50) 0.27
Previous medical history
Hypertension 84 (55) 75 (49) 0.24
Myocardial infarct 23 (15) 21 (14) 0.49
Diabetes 20 (13) 26 (17) 0.42
Asthma/COPD 26 (17) 17 (11) 0.14
Medication
On frusemide before referral 29 (19) 41 (27) 0.23
On ACE-I before referral 45 (29) 36 (24) 0.54
Clinical, imaging, and laboratory values
Heart rate (beats/min)* 74 (15) 73 (15) 0.23
Systolic BP (mm Hg)* 146 (23) 145 (23) 0.62
Diastolic BP (mm Hg)* 80 (15) 79 (16) 0.46
Atrial fibrillation 15 (9) 20 (13) 0.64
LVEDD (mm)* 52.2 (7.9) 51.9 (7.7) 0.77
LVESD (mm)* 36.6 (10.3) 36.4 (8.8) 0.85
FS (%)* 31.3 (9.7) 32.0 (9.1) 0.57
LV mass (g)* 189.8 (63.5) 192.5 (77.6) 0.78
6-min walk distance (m)* 259 (178) 265 (174) 0.78
N-BNP (pmol/l)* 121 (226) 114 (161) 0.76
Panel diagnosis of heart failure
Heart failure (n) 43 34
Not heart failure (n) 109 119 0.24
Values represent n (%) unless otherwise stated. *Mean (standard deviation).
ACE-I  angiotensin-converting enzyme inhibitor; BP  blood pressure; COPD  chronic obstructive pulmonary disease;
FS  fractional shortening; LVEDD  left ventricular end-diastolic dimension; LVESD  left ventricular end-systolic
dimension; N-BNP  N-terminal pro-brain natriuretic peptide.
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The effect of N-BNP on diagnostic accuracy (Table 3). At
the GP review visit, each GP reviewed the patient either
with the patient’s N-BNP result (BNP group) or using
customary clinical assessment (control group). The provi-
sional diagnosis made at the initial GP visit was then
reviewed. The diagnostic accuracy in the N-BNP group
improved 21% (from 49% diagnoses correct to 70% correct).
This compared with an improvement of 8% in the control
group (from 52% diagnoses correct to 59% correct, p 
0.002, Table 3, Fig. 2). The increase in diagnostic accuracy
in the BNP group was mainly due to an increase of GPs
correctly ruling out HF (Table 3). In the BNP group, 30
patients initially thought to have HF were correctly re-
characterized as not having HF when clinically reviewed
with the N-BNP result, compared with 14 patients correctly
re-characterized in the control group using customary clin-
ical review (Table 3). Hence, the N-BNP results improved
accuracy in the diagnosis of HF by GPs, when compared
with customary clinical assessment.
The GPs involved in the study referred a median of two
patients (range 1 to 14), with a median interval between
referral of 184 days (IQR 50 to 355) over the recruitment
period of 24 months. Of the GPs who referred more than
two patients to the study (n 57, 62%), the median interval
between referral of patients to the study was 42 days (IQR
12 to 106). Trends in diagnostic accuracy in this group of
GPs were examined for a learning effect over the course of
the study. Diagnostic accuracy did not change over the
course of the study for these GPs. In addition, patterns of
diagnostic accuracy in the subgroup of GPs with patients
randomized to the BNP group and then patients random-
ized to the control group during the study (n  7) were
examined for contamination. Diagnostic accuracy remained
unchanged over the course of the study in this group of GPs
(p  0.63).
Multivariate logistic regression was performed to examine
if N-BNP still improved diagnostic accuracy when patients
had been commenced on loop diuretics or ACE inhibitor
medications at the initial GP visit, or if patients were being
treated with these medications before this visit. The
N-BNP had a clear beneficial effect on the diagnostic
accuracy after controlling for treatment (p  0.012). In
addition, in a multivariate model the delay between the
initial GP visit and the study visit did not alter the effect of
N-BNP on diagnostic accuracy (p  0.76).
Characterization of patients with HF. The characteristics
of the 77 patients with a confirmed diagnosis of HF are
shown in Table 4. The patients with HF were more likely to
be male and to have diabetes, AF, or a history of myocardial
infarction but not hypertension. The patients with HF were
more likely to be receiving frusemide and ACE inhibitor
medication at the study visit. Echocardiographic parameters
(LV size, function, and LV mass) and cardio-thoracic ratio
were significantly different for patients with HF (Table 4).
Forty-three (56%) of the patients with HF had normal LV
systolic function. Patients with HF had significantly higher
mean N-BNP, 286 pmol/l (SD 319) compared with 61
pmol/l (SD 67) in those patients without HF.
Figure 2. Receiver operating characteristic curve for N-BNP in the
diagnosis of heart failure. Area under the curve  0.85.
Table 3. Change in Correct Diagnoses of Patients Presenting With Suspected HF in BNP and Control Groups
GP Diagnosis at
Initial GP Visit
GP Diagnosis at
Final GP Visit
Change in Correctly
Diagnosed Patients p Value
Control group (n  153)
Correct diagnosis of HF, n (%) 33 (21) 31 (20) 2
Correct diagnosis of not HF, n (%) 46 (30) 60 (39) 14
Total correct diagnoses, n (%) 79 (51.6) 91 (59.5) 12 (7.9%) 0.21
BNP group (n  152)
Correct diagnosis of HF, n (%) 37 (24) 39 (26) 2
Correct diagnosis of not HF, n (%) 37 (24) 67 (44) 30
Total correct diagnoses, n (%) 74 (49) 106 (70) 32 (21%) 0.003
The table shows absolute numbers of patients. The change in diagnostic accuracy is change in diagnosis between the initial GP visit and the final GP visit where each patient
was reviewed with his or her N-BNP result (BNP group) or according to customary clinical assessment (control group). Overall improvement in correct diagnoses between groups
(control vs. BNP) was 13% (95% CI 5.5, 21.0), p  0.002.
BNP  brain natriuretic peptide; CI  confidence interval; GP  general practitioner; HF  heart failure; N-BNP  amino terminal brain natriuretic peptide.
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DISCUSSION
Heart failure is difficult to diagnose in primary care (28).
Patients are often elderly with comorbidity, symptoms may
be mild, routine clinical assessment lacks specificity, and
echocardiography may not be universally available (29).
These factors contribute to considerable diagnostic prob-
lems that are more important and frequent than often
recognized. Over-diagnosis of HF in the community is a
well-documented phenomenon, with only a quarter to a
third of patients with suspected HF by GPs in several
studies having HF confirmed on further cardiologic assess-
ment (1,2,9). In the current study, GPs suspected that 70%
of patients had HF, compared with the final panel diagnosis
of definite HF in only 25% of patients.
The study demonstrated that the availability of N-BNP
to GPs resulted in an absolute improvement in diagnostic
accuracy of 21% compared with only 8% with clinical review
alone (p 0.002). The main impact was in enabling GPs to
correctly rule out HF. This is consistent with the finding of
high negative predictive value of BNP in previous studies
(8,9). This clearly has important implications for the im-
provement in the accuracy of diagnosis of HF in primary
care.
Previous studies examining the potential role of BNP
measurement in the diagnosis of HF have concluded that it
is likely to be of benefit (6–9). However, these studies had
several limitations, including not recruiting consecutive
symptomatic patients (6) and not comparing BNP with
standardized criteria for the clinical diagnosis of HF (30).
Several studies were conducted in the acute-care hospital
setting and may not be generalizable to primary care (6–8).
Screening studies have indicated that false positive results
may present problems in elderly primary care populations in
which other medical conditions known to elevate natriuretic
peptide levels are common (10). Importantly, none of the
previous studies involved random allocation of the N-BNP
result to the physician. This study is the first prospective,
randomized controlled trial of the effectiveness of N-BNP
in a community care setting. This study design has extended
the previous studies of BNP in the assessment of patients
with suspected HF to evaluate the impact of this test on
clinical decision-making; a final step in the evidence base of
clinical diagnosis (31). The study was conducted in the
Table 4. Clinical Characteristics by Presence of HF
No Heart Failure
(n  228)
Heart Failure
(n  77) p Value
Age (yrs)* 72 (11) 74 (11) 0.16
Gender
Female 159 (70) 39 (51) —
Male 69 (30) 38 (49) 0.004
Symptoms
Dyspnea only 90 (39) 28 (36) —
Edema only 34 (15) 4 (5) —
Both symptoms 104 (46) 45 (58) 0.05
Previous medical history
Hypertension 122 (53) 37 (48) 0.5
Myocardial infarct 18 (8) 26 (34) 0.0001
Diabetes 24 (10) 22 (28) 0.0001
Asthma/COPD 34 (15) 9 (12) 0.57
Medications
On loop diuretic before referral 41 (18) 29 (38) 0.0001
On ACE-I before referral 45 (20) 36 (47) 0.0001
Commenced loop diuretic at GP1 36 (16) 30 (39) 0.001
Commenced ACE-I at GP1 20 (19) 17 (22) 0.002
Clinical, imaging, and laboratory values
Heart rate (beats/min)* 74 (15) 73 (16) 0.75
Systolic BP (mm Hg)* 148 (22) 140 (24) 0.007
Diastolic BP (mm Hg)* 80 (14) 76 (17) 0.024
Serum creatinine (mmol/l) 0.09 (0.03) 0.114 (0.04) 0.0001
Atrial fibrillation, n (%) 12 (5) 23 (30) 0.0019
Major ECG abnormality, n (%) 72 (31) 59 (77) 0.001
Cardiothoracic ratio (%)* 0.504 (0.06) 0.58 (0.08) 0.0001
LVEDD (mm)* 50.18 (5.8) 57.46 (10) 0.0001
LVESD (mm)* 33.3 (6.3) 44.7 (11.5) 0.0001
FS (%)* 34.3 (7.7) 23.9 (9.7) 0.0001
LA area (cm2)* 20.7 (4.8) 26.2 (5.9) 0.0001
LV mass (g)* 177.6 (56.7) 229.7 (90.4) 0.0001
6-min walk distance (m)* 289.9 (166) 179.8 (179) 0.0001
N-BNP (pmol/l)* 61 (67) 286 (319) 0.0001
Variables are expressed as n (%) unless otherwise specified; *mean (SD).
ECG  electrocardiographic; GP1  initial GP visit; HF  heart failure; LA  left atrium; other abbreviations as in Table 2.
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day-to-day setting of primary health care delivery in which
other diagnostic strategies commonly used by GPs, such as
empirical prescribing of treatment and subsequent clinical
reassessment, continued to operate.
New diagnostic tests must be assessed against agreed
clinical diagnostic criteria for HF rather than associated
surrogates such as an arbitrary level of LV ejection fraction.
The trial used a rigorous clinical diagnosis of HF made by
a blinded, independent panel according to standard criteria
(26). By showing a clear improvement in the accuracy of
diagnosis of HF in primary care, this study moves the use of
BNP from the field of observational studies to that of
community-based clinical trials.
The simplicity of a single blood test that can be taken
without special preparation or sampling conditions makes
widespread use of this test feasible in clinical practice,
including primary care settings. Although N-BNP im-
proved diagnostic accuracy in this study, other tests such as
echocardiography may still be required once HF has been
diagnosed (32). However, the use of N-BNP may reliably
rule out HF, allowing the targeted use of tests such as
echocardiography in clinical settings in which availability is
limited. The availability of portable BNP meters designed
for point-of-care use and centralized, automated N-BNP
assays using pre-existing laboratory platforms indicates that
BNP measurement in many settings is becoming common
and turn-around time more rapid.
Study limitations. This study examined a cohort of ambu-
latory symptomatic patients in primary care. The study
design ensured that all patients attended a review visit with
their referring GPs as part of the study. Clinical review may
not be universal practice in primary care, but the study
design combined the need for a standardized study protocol
in both control and BNP groups while operating in the
context of day-to-day health care delivery.
In clinical practice, natriuretic peptide measurement
would occur at initial presentation, unlike this study, in
which it was performed at a study visit a median of seven
days later. However, N-BNP had a clear beneficial effect on
the diagnostic accuracy of HF despite this delay and despite
the initiation of empirical therapy in many patients.
Selection bias is a potential problem in every diagnostic
study. Participating GPs were encouraged to refer all
patients presenting with dyspnea and/or edema to minimize
selection bias and allow the evaluation of the diagnostic test
in a consecutive sequence of primary care patients. The
patients recruited in this study were typical of those in
primary care with a provisional diagnosis of HF. Approxi-
mately half were women, mean age was in the mid 70s, and
comorbidity was common.
Conclusions. The Natriuretic Peptides in the Community
study is the first prospective, randomized controlled trial
showing the positive effect of N-BNP measurement on the
diagnostic accuracy of HF in primary care. The change in
the percentage of improvement in correct diagnoses of the
BNP group (21%) compared with the control group (8%)
allows calculation of the number needed to diagnose:
measurement of N-BNP in seven patients with a provisional
diagnosis of HF is needed to re-characterize one patient
correctly.
This study shows that N-BNP measurement significantly
improves the diagnostic accuracy of HF by GPs. Amino-
terminal pro-brain natriuretic peptide is particularly impor-
tant in decreasing the over-diagnosis of HF that occurs in
primary care. This study now allows the evidence-based
recommendation that availability of N-BNP measurement
to GPs will significantly improve the diagnostic accuracy of
HF in primary care.
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APPENDIX
For the full listing of Auckland general practitioners who
participated in this study, please see the online appendix for
this article in the November 5, 2003 issue of JACC at
www.cardiosource.com/jacc.html.
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